In insulin-resistant states, such as type 2 diabetes and NAFLD, hepatic overproduction of SeP exacerbates metabolic dysfunction by inhibiting insulin action in peripheral tissues (24, 73). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.